Disease Detail


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown PP-121 esophageal cancer not applicable detail...
Unknown unknown BI-847325 esophageal cancer not applicable detail...
MET amp AMG 337 esophageal cancer sensitive detail...
Unknown unknown Regorafenib esophageal cancer not applicable detail...
Unknown unknown Cetuximab + Cisplatin + Paclitaxel + Radiotherapy esophageal cancer no benefit detail...
ERBB2 amp Ibrutinib esophageal cancer sensitive detail...
Unknown unknown TAS-120 esophageal cancer not applicable detail...
ERBB2 positive ZW25 esophageal cancer predicted - sensitive detail...
Unknown unknown DKN-01 + Paclitaxel esophageal cancer not applicable detail...
KRAS G12C RMC-4550 esophageal cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01037790 Phase II Palbociclib PD 0332991 in Treating Patients With Refractory Solid Tumors Recruiting
NCT01128387 Phase Ib/II Fluorouracil Panitumumab Cisplatin Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer Terminated
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Suspended
NCT01522768 Phase II Afatinib + Trastuzumab Afatinib (BIBW 2992) and Trastuzumab in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer Recruiting
NCT01848756 Phase Ib/II SNX-5422 Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Terminated
NCT01928290 Phase II Trastuzumab FOLFIRINOX Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer Active, not recruiting
NCT02375958 Phase I PCA062 PCA062 in pCAD-positive Tumors. Completed
NCT02569242 Phase III Docetaxel + Paclitaxel Nivolumab Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer Active, not recruiting
NCT02749513 Phase I Itraconazole Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients Recruiting
NCT02795156 Phase II Afatinib Regorafenib Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Recruiting
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed
NCT02963831 Phase Ib/II ONCOS-102 + MEDI4736 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Recruiting
NCT02970539 Phase I Oraxol + Ramucirumab Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers Recruiting
NCT03044613 Phase I Nivolumab + Ipilimumab + Carboplatin + Paclitaxel Nivolumab + Carboplatin + Paclitaxel Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer Recruiting
NCT03126110 Phase Ib/II INCAGN01876 + Nivolumab + Ipilimumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Recruiting
NCT03132922 Phase I Autologous MAGE-A4 C1032 TCR-modified T cells MAGE-A4c1032T for Multi-Tumor Recruiting
NCT03144661 Phase I INCB062079 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Recruiting
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03330561 Phase I PRS-343 PRS-343 in HER2-Positive Solid Tumors Recruiting
NCT03477162 Phase 0 Metformin Metformin Pharmacology in Human Cancers: A Proof of Principle Study Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Recruiting
NCT03720678 Phase I AB928 + mFOLFOX-6 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal (GI) Malignancies Recruiting
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Recruiting
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting